Results 111 to 120 of about 3,980,763 (249)

Experience with siponimod for treating patients with secondary progressive multiple sclerosis in the Moscow Region

open access: yesНеврология, нейропсихиатрия, психосоматика
Siponimod is a sphingosine-1-phosphate receptor modulator approved in most countries for the treatment of secondary progressive multiple sclerosis (SPMS) with activity.
Yu. A. Belova   +3 more
doaj   +1 more source

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach   +23 more
wiley   +1 more source

The progressive tax [PDF]

open access: yes
This article describes the argumentative structure of Hayek on the relationship between power to tax and the progressive tax. It is observed throughout its work giving special attention to two works: The Constitution of Liberty (1959) and Law ...
Estrada, Fernando
core  

The Maine Progressive - Vol. 4, No. 4 : January 1990 [PDF]

open access: yes, 1990
If Maine is to be a more progressive society, people must make a commitment to work toward it. We hope that The Maine Progressive will broaden the base of support for progressive causes and bring together active people involved with many issues from all ...
Maine Progressive
core  

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi   +9 more
wiley   +1 more source

Review essay%253A Can progressive education save America’s schools%253F

open access: yes, 2016
In Loving Learning%253A How Progressive Education Can Save America%252339%253Bs Schools, Tom Little and Katherine Ellison describe Toms experiences, personal joumey and knowledge of progressive education.
John L. Pecore
core  

The Maine Progressive - Vol. 1, No. 3 : December 1986 [PDF]

open access: yes, 1986
If Maine is to be a more progressive society, people must make a commitment to work toward it. We hope that The Maine Progressive will broaden the base of support for progressive causes and bring together active people involved with many issues from all ...
Maine Progressive
core  

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Review essay: Can progressive education save America’s schools?

open access: yes, 2016
In Loving Learning: How Progressive Education Can Save America's Schools, Tom Little and Katherine Ellison describe Tom’s experiences, personal joumey and knowledge of progressive education.
John L. Pecore
core  

The Maine Progressive - Vol. 4, No. 11 : August 1990 [PDF]

open access: yes, 1990
If Maine is to be a more progressive society, people must make a commitment to work toward it. We hope that The Maine Progressive will broaden the base of support for progressive causes and bring together active people involved with many issues from all ...
Maine Progressive
core  

Home - About - Disclaimer - Privacy